Safety, tolerability, pharmacokinetics, and Aβ levels after short-term administration of R-flurbiprofen in healthy elderly individuals

Alzheimer Disease and Associated Disorders

Volumn 21, Issue 4, 2007, Pages 292-299

  Galasko, Douglas R ^a   Graff Radford, Neil ^b   May, Susanne ^a   Hendrix, Suzanne ^c,e   Cottrell, Barbara A ^a   Sagi, Sarah A ^a   Mather, Gary ^c,e   Laughlin, Mark ^c,e   Zavitz, Kenton H ^c,e   Swabb, Edward ^c,e   Golde, Todd E ^b   Murphy, Michael P ^b,d   Koo, Edward H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c Myriad Pharmaceuticals Inc   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e Myriad Inc

Author keywords

Alzheimer disease; R flurbiprofen; Treatment

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; PLACEBO; TARENFLURBIL;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; KIDNEY DISEASE; MALE; MENTAL DISEASE; NEUROLOGIC DISEASE; NORMAL HUMAN; OCCULT BLOOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PROTEIN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLURBIPROFEN; HUMANS; MALE; MIDDLE AGED; TIME;

EID: 37349104196     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e31815d1048     Document Type: Article

References (21)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353-356.
2. Aisen PS, Schafer KA, Grundman M, et al. Alzheimer's Disease Cooperative Study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289:2819-2826.
3. Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30:1204-1215.
4. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414:212-216.
5. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003;112:440-449.
6. Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. 2000;20:5709-5714.
7. Lleo A, Berezovska O, Herl L, et al. Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med. 2004;10:1065-1066.
8. Beher D, Clarke EE, Wrigley JD, et al. Selected non-steroidal antiinflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J Biol Chem. 2004;279:43419-43426.
9. Golde TE. Alzheimer disease therapy: can the amyloid cascade be halted? J Clin Invest. 2003;111:11-18.
10. Morihara T, Chu T, Ubeda O, et al. Selective inhibition of Abeta42 production by NSAID R-enantiomers. J Neurochem. 2002;83:1009-1012.
11. Geisslinger G, Muth-Selbach U, Coste O, et al. Inhibition of noxious stimulus-induced spinal prostaglandin E2 release by flurbiprofen enantiomers: a microdialysis study. J Neurochem. 2000;74:2094-2100.
12. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65-70.
13. Black S, Wilcock GK, Haworth J, et al. Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective Ab42-lowering agent, in mild Alzheimer's Disease (AD): results of a 12-month phase 2 trial and 1-year follow-on study. Neurology. 2006;66(suppl 2):A347.
14. Siemers ER, Quinn JF, Kaye J, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. 2006;66:602-604.
15. El Mouedden M, Vandermeeren M, Meert T, et al. Reduction of Abeta levels in the Sprague Dawley rat after oral administration of the functional gamma-secretase inhibitor, DAPT: a novel nontransgenic model for Abeta production inhibitors. Curr Pharm Des. 2006;12:671-676.
16. Cirrito JR, May PC, O'Dell MA, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23:8844-8853.
17. Bateman RJ, Munsell LY, Morris JC. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12:856-861.
18. Yan Q, Zhang J, Liu H, et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci. 2003;23:7504-7509.
19. Jantzen PT, Connor KE, DiCarlo G, et al. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci. 2002;22:2246-2254.
20. Yao Y, Chinnici C, Tang H, et al. Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis. J Neuroinflamm. 2004;1:1-21.
21. Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal antiinflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology. 2004;23:159-169.